RSS_IDENT_s_31077629_a_1_4
 Conclusions SMs are reliably detected in urinary cpDNA and cfDNA. The technical capability to identify very low MAFs is essential to reliably detect UBC, regardless of the use of cpDNA or cfDNA. This 23‐gene panel shows promise for the non‐invasive diagnosis and risk stratification of UBC. Abbreviations AKT1 AKT serine/threonine kinase 1 BCPP Bladder Cancer Prognosis Programme BRAF B‐Raf proto‐oncogene, serine/threonine kinase C3orf70 chromosome 3 open reading frame 70 CDKN1A cyclin‐dependent kinase inhibitor 1A CDKN2A cyclin‐dependent kinase inhibitor 2A cfDNA cell‐free DNA CIS carcinoma in situ (Tis) cpDNA cell‐pellet DNA CREBBP CREB binding protein CTNNB1 catenin β1 EAU European Association of Urology ELF3 E74 like ETS transcription factor 3 EORTC European Organisation for the Research and Treatment of Cancer ERBB2 Erb‐B2 receptor tyrosine kinase 2 ERBB3 Erb‐B2 receptor tyrosine kinase 3 ERCC2 ERCC excision repair 2, TFIIH core complex helicase subunit FBXW7 F‐box and WD repeat domain containing 7 FGFR3 fibroblast growth factor receptor 3 HR hazard ratio HRAS HRas proto‐oncogene, GTPase KDM6A lysine demethylase 6A KRAS KRAS proto‐oncogene, GTPase MAF mutant allele frequency (N)MIBC (non‐)muscle‐invasive bladder cancer NRAS NRAS proto‐oncogene, GTPase PIK3CA phosphatidylinositol‐4,5‐bisphosphate 3‐kinase, catalytic subunit α pT pathological T stage RHOB Ras homolog family member B RXRA retinoid X receptor α SF3B1 splicing factor 3b subunit 1 SM somatic mutation TERT telomerase reverse transcriptase TP53 tumour protein P53 TURBT transurethral resection of bladder tumour UBC urothelial bladder cancer UMI unique molecular identifiers
